- Development-stage biotech Hillstream BioPharma ( NASDAQ: HILS ) climbed ~107% on Tuesday after announcing an exclusive option agreement with Dana-Farber Cancer Institute for technology linked to oncology gene MUC1.
- Per the terms, Hillstream ( HILS ) will have the option to convert the technology into an exclusive license agreement, after which the company can develop anti-MUC1-C antibodies in combination with its Quatramer-based lead candidate HSB-1216.
- The company highlighted the benefit of combining MUC1-C antibodies with HSB-1216 in eliminating cancer stem cells (CSCs) which is thought to play a role in long-term responses and cures.
- “This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients,” Chief Executive of Hillstream ( HILS ) Randy Milby said.
- Read: Hillstream ( HILS ) made its public debut in January 2022, seeking $15M in gross proceeds.
For further details see:
Hillstream adds over 100% on licensing deal with Dana-Farber